The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV
Lisa O’Brien, Nathan Shaffer, Nalinee Sangrujee & Taiwo O Abimbola
Volume 92, Number 3, March 2014, 162-170
Table 6. Percentage change in incremental costa per woman of Option B+b relative to Option Bc over 5 years postpartum, by CD4+ cell count and for fixed-dose and non-fixed-dose pricing of antiretrovirals
|Breastfeeding status and duration||CD4+ count 350–500 cells/µl
||CD4+ count > 500 cells/µl
|Incremental cost, non-fixed-dose pricing (US$)||Incremental cost, fixed-dose pricing (US$)||Percentage change||Incremental cost, non-fixed-dose pricing (US$)||Incremental cost, fixed-dose pricing (US$)||Percentage change|
a All costs are in 2011 United States dollars (US$).
b Option B+ comprises a triple antiretroviral (ARV) regimen initiated during pregnancy and continued for life.
c Option B comprises a maternal triple ARV regimen, typically consisting of the recommended first-line antiretroviral therapy, during pregnancy and throughout breastfeeding, in combination with 6 weeks of daily nevirapine for the infant, regardless of infant feeding method.